Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179244 · ClinicalTrials.gov registry record · Phase 3
Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression
A Phase 3 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00179244 is a Phase 3 study that has completed, run by Vanderbilt University. The registered enrollment target is 30 participants.
The verdict
NCT00179244, a Phase 3 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.
Interventions
- DRUG Rispridone (drug) and Bupropion ER (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179244
The ClinicalTrials.gov registry entry for NCT00179244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rispridone (drug) and Bupropion ER (drug) is the first listed.
NCT00179244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179244 about?
NCT00179244 is a clinical study titled "Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression". The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.
What is the current status of trial NCT00179244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-07. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00179244?
The interventions under investigation include: Rispridone (drug) and Bupropion ER (drug) (DRUG).
Who is sponsoring clinical trial NCT00179244?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.